Skip to main content

Affimed N.V. (AFMDQ)

OTC Pink Sheets (US) Healthcare BiotechnologyView data quality →
39.0Poor

ValueMarkers Composite Index

Top 4%#42,911 of 44,714

DCF data not available

Piotroski
0/9
Weak
Beneish
5.00
High Risk
Altman
-10.54
Distress
DCF Value
-
N/A
ROIC
-137.4%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Affimed N.V. (AFMDQ) — VMCI valuation read

The headline on Affimed N.V. (AFMDQ) is a 39/100 VMCI score, set against a Healthcare sector median of 50. That 11-point below-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value drag is in the data.

AFMDQ insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** AFMDQ trades at 27.0x earnings, 50% above the Healthcare median of 18.0x sets the value side. ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of 1.9x is the rate-sensitivity line to watch sets the risk side, the three lines a value buyer reads first on AFMDQ.

AFMDQ rose 1.9% over the trailing 7 days, with a -23.4% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in AFMDQ’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.